Omeros (NASDAQ:OMER) Raised to “Strong-Buy” at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Omeros (NASDAQ:OMER) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

A number of other analysts have also issued reports on OMER. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research note on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Thursday. StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Finally, Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday. They issued a “buy” rating and a $9.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Omeros presently has an average rating of “Hold” and an average price target of $9.00.

Omeros Stock Down 2.9 %

Omeros stock opened at $6.75 on Thursday. Omeros has a 52 week low of $1.38 and a 52 week high of $7.51. The business’s 50-day moving average price is $4.14 and its 200 day moving average price is $4.10.

Hedge Funds Weigh In On Omeros

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after purchasing an additional 81,348 shares during the last quarter. Geode Capital Management LLC lifted its stake in Omeros by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares during the last quarter. State Street Corp lifted its stake in Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 3,839 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Omeros by 4.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after buying an additional 18,454 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 31,081 shares during the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.